Adjuvant Chemotherapy and Immunotherapy

How it works

Benefits

Dosage & preparation

Comparisons

Evidence quality

Highlighted claims

• The trial regimen uses pucotenlimab, temozolomide, and cisplatin for six 3-week systemic therapy cycles. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
• Chinese randomized phase II data support adjuvant temozolomide plus cisplatin after resection of mucosal melanoma. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
• Temozolomide-cisplatin improved relapse-free and overall survival compared with observation and high-dose interferon in a randomized phase II trial. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
• Chemotherapy is presented as a rational backbone for combination with PD-1 inhibition. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial
• Pembrolizumab plus temozolomide showed better progression-free survival than temozolomide-based chemotherapy alone in advanced melanoma retrospective data. — Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial